ArticleJournal of virology2012
Identification of a pyridopyrimidinone inhibitor of orthopoxviruses from a diversity-oriented synthesis library.
Article in Journal of virology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Identification of natural products and synthetic analogs which inhibit microsporidia spores and prevent infection.Journal of invertebrate pathology · 2026Article
- Research Review on Inhibitors of Lumpy Skin Disease Virus: From Biological Characteristics, Drug Repurposing, to Computer-Aided Drug Design.International journal of microbiology · 2026Review
- A review of Mpox: Biological characteristics, epidemiology, clinical features, diagnosis, treatment, and prevention strategies.Exploration (Beijing, China) · 2025Review
- Monkeypox: Origin, Transmission, Clinical Manifestations, Prevention, and Therapeutic Options.Interdisciplinary perspectives on infectious diseases · 2025Review
- Natural Immunomodulatory Agents as a Complementary Therapy for Poxviruses.Advances in experimental medicine and biology · 2024Review
- Identification of Small Molecules with Improved Potency against Orthopoxviruses from Vaccinia to Smallpox.Antimicrobial agents and chemotherapy · 2022Article
- Article
- Suppression of Poxvirus Replication by Resveratrol.Frontiers in microbiology · 2017Article
- Activation of stress response pathways promotes formation of antiviral granules and restricts virus replication.Molecular and cellular biology · 2014Article
- Vaccinia reporter viruses for quantifying viral function at all stages of gene expression.Journal of visualized experiments : JoVE · 2014Article
- The master regulator of the cellular stress response (HSF1) is critical for orthopoxvirus infection.PLoS pathogens · 2014Article
- Orthopoxvirus targets for the development of new antiviral agents.Antiviral research · 2012Review
- Gold catalyzed cyclization of alkyne-tethered dihydropyrimidones.Organic letters · 2011Article
- Probing the virus host interaction in high containment: an approach using pooled short hairpin RNA.Assay and drug development technologiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Orthopoxviruses include the prototypical vaccinia virus, the emerging infectious agent monkeypox virus, and the potential biothreat variola virus (the causative agent of smallpox). There is currently no FDA-approved drug for humans infected with orthopoxviruses. We screened a diversity-oriented synthesis library for new scaffolds with activity against vaccinia virus. This screen identified a nonnucleoside analog that blocked postreplicative intermediate and late gene expression. Viral genome replication was unaffected, and inhibition could be elicited late in infection and persisted upon drug removal. Sequencing of drug-resistant viruses revealed mutations predicted to be on the periphery of the highly conserved viral RNA polymerase large subunit. Consistent with this, the compound had broad-spectrum activity against orthopoxviruses in vitro. These findings indicate that novel chemical synthesis approaches are a potential source for new infectious disease therapeutics and identify a potentially promising candidate for development to treat orthopoxvirus-infected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.